Literature DB >> 27542298

Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology.

Joan Ramon Guitart1, Jodi L Johnson2, Wade W Chien3.   

Abstract

Designer nucleases have gained widespread attention for their ability to precisely modify genomic DNA in a programmable manner. These genome-editing nucleases make double-stranded breaks at specified loci, and desired changes can be made to modify, ablate, or excise target genes. This technology has been used widely to develop human disease models in laboratory animals and to study gene functions by silencing, activating, or modifying them. Furthermore, the recent discovery of a bacterially derived programmable nuclease termed clustered regularly interspaced palindromic repeats (CRISPR)-associated protein 9 (Cas9) has revolutionized the field because of its versatility and wide applicability. In this article, we discuss various modalities used to achieve genome editing with an emphasis on CRISPR-Cas9. We discuss genome-editing strategies to either repair or ablate target genes, with emphasis on their applications for investigating dermatological diseases. Additionally, we highlight preclinical studies showing the potential of genome editing as a therapy for congenital blistering diseases and as an antimicrobial agent, and we discuss limitations and future directions of this technology.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27542298      PMCID: PMC5042211          DOI: 10.1016/j.jid.2016.06.007

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Gabriela Petrof; Su M Lwin; Magdalena Martinez-Queipo; Alya Abdul-Wahab; Simon Tso; Jemima E Mellerio; Ineke Slaper-Cortenbach; Jaap J Boelens; Jakub Tolar; Paul Veys; Mercy Ofuya; Janet L Peacock; Anna E Martinez; John A McGrath
Journal:  J Invest Dermatol       Date:  2015-04-23       Impact factor: 8.551

2.  TALEN-based gene correction for epidermolysis bullosa.

Authors:  Mark J Osborn; Colby G Starker; Amber N McElroy; Beau R Webber; Megan J Riddle; Lily Xia; Anthony P DeFeo; Richard Gabriel; Manfred Schmidt; Christof von Kalle; Daniel F Carlson; Morgan L Maeder; J Keith Joung; John E Wagner; Daniel F Voytas; Bruce R Blazar; Jakub Tolar
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

3.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

Review 4.  Editing the epigenome: technologies for programmable transcription and epigenetic modulation.

Authors:  Pratiksha I Thakore; Joshua B Black; Isaac B Hilton; Charles A Gersbach
Journal:  Nat Methods       Date:  2016-02       Impact factor: 28.547

5.  DNA nicks promote efficient and safe targeted gene correction.

Authors:  Luther Davis; Nancy Maizels
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

6.  Engineered CRISPR-Cas9 nucleases with altered PAM specificities.

Authors:  Benjamin P Kleinstiver; Michelle S Prew; Shengdar Q Tsai; Ved V Topkar; Nhu T Nguyen; Zongli Zheng; Andrew P W Gonzales; Zhuyun Li; Randall T Peterson; Jing-Ruey Joanna Yeh; Martin J Aryee; J Keith Joung
Journal:  Nature       Date:  2015-06-22       Impact factor: 49.962

7.  Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant.

Authors:  Sandra P Melo; Leszek Lisowski; Elizaveta Bashkirova; Hanson H Zhen; Kirk Chu; Douglas R Keene; M Peter Marinkovich; Mark A Kay; Anthony E Oro
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

8.  Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.

Authors:  Takeshi Maruyama; Stephanie K Dougan; Matthias C Truttmann; Angelina M Bilate; Jessica R Ingram; Hidde L Ploegh
Journal:  Nat Biotechnol       Date:  2015-03-23       Impact factor: 54.908

9.  Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.

Authors:  David Bikard; Chad W Euler; Wenyan Jiang; Philip M Nussenzweig; Gregory W Goldberg; Xavier Duportet; Vincent A Fischetti; Luciano A Marraffini
Journal:  Nat Biotechnol       Date:  2014-10-05       Impact factor: 54.908

10.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

View more
  6 in total

Review 1.  Research Techniques Made Simple: Murine Models of Human Psoriasis.

Authors:  Jason E Hawkes; Jonas A Adalsteinsson; Johann E Gudjonsson; Nicole L Ward
Journal:  J Invest Dermatol       Date:  2018-01       Impact factor: 8.551

2.  Research Techniques Made Simple: Delivery of the CRISPR/Cas9 Components into Epidermal Cells.

Authors:  Huishan Shi; Jos P H Smits; Ellen H van den Bogaard; Matthew G Brewer
Journal:  J Invest Dermatol       Date:  2021-06       Impact factor: 7.590

3.  COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Stefan Hainzl; Patricia Peking; Thomas Kocher; Eva M Murauer; Fernando Larcher; Marcela Del Rio; Blanca Duarte; Markus Steiner; Alfred Klausegger; Johann W Bauer; Julia Reichelt; Ulrich Koller
Journal:  Mol Ther       Date:  2017-07-13       Impact factor: 11.454

Review 4.  Mutation-Directed Therapeutics for Neurofibromatosis Type I.

Authors:  Andre Leier; David M Bedwell; Ann T Chen; George Dickson; Kim M Keeling; Robert A Kesterson; Bruce R Korf; Tatiana T Marquez Lago; Ulrich F Müller; Linda Popplewell; Jiangbing Zhou; Deeann Wallis
Journal:  Mol Ther Nucleic Acids       Date:  2020-04-29       Impact factor: 8.886

Review 5.  An Insight into Modern Targeted Genome-Editing Technologies with a Special Focus on CRISPR/Cas9 and its Applications.

Authors:  Fatima Akram; Sania Sahreen; Farheen Aamir; Ikram Ul Haq; Kausar Malik; Memoona Imtiaz; Waqas Naseem; Narmeen Nasir; Hafiza Mariam Waheed
Journal:  Mol Biotechnol       Date:  2022-04-26       Impact factor: 2.860

Review 6.  Research Techniques Made Simple: CRISPR Genetic Screens.

Authors:  Auke B C Otten; Bryan K Sun
Journal:  J Invest Dermatol       Date:  2020-04       Impact factor: 8.551

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.